<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hatzakis, Angelos</style></author><author><style face="normal" font="default" size="100%">Karabinis, Andreas</style></author><author><style face="normal" font="default" size="100%">Roussos, Sotirios</style></author><author><style face="normal" font="default" size="100%">Pantazis, Nikos</style></author><author><style face="normal" font="default" size="100%">Degiannis, Dimitrios</style></author><author><style face="normal" font="default" size="100%">Chaidaroglou, Antigoni</style></author><author><style face="normal" font="default" size="100%">Petsios, Konstantinos</style></author><author><style face="normal" font="default" size="100%">Pavlopoulou, Ioanna</style></author><author><style face="normal" font="default" size="100%">Tsiodras, Sotirios</style></author><author><style face="normal" font="default" size="100%">Paraskevis, Dimitrios</style></author><author><style face="normal" font="default" size="100%">Sypsa, Vana</style></author><author><style face="normal" font="default" size="100%">Psichogiou, Mina</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination.</style></title><secondary-title><style face="normal" font="default" size="100%">Vaccines (Basel)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Vaccines (Basel)</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Feb 13</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">10</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Several lines of evidence suggest that binding SARS-CoV-2 antibodies such as anti-SARS-CoV-2 RBD IgG (anti-RBD) and neutralising antibodies (NA) are correlates of protection against SARS-CoV-2, and the correlation of anti-RBD and NA is very high. The effectiveness (VE) of BNT162b2 in preventing SARS-CoV-2 infection wanes over time, and this reduction is mainly associated with waning immunity, suggesting that the kinetics of antibodies reduction might be of interest to predict VE. In a study of 97 health care workers (HCWs) vaccinated with the BNT162b2 vaccine, we assessed the kinetics of anti-RBD 30-250 days after vaccination using 388 individually matched plasma samples. Anti-RBD levels declined by 85%, 92%, and 95% at the 4th, 6th, and 8th month from the peak, respectively. The kinetics were estimated using the trajectories of anti-RBD by various models. The restricted cubic splines model had a better fit to the observed data. The trajectories of anti-RBD declines were statistically significantly lower for risk factors of severe COVID-19 and the absence of vaccination side effects. Moreover, previous SARS-CoV-2 infection was associated with divergent trajectories consistent with a slower anti-RBD decline over time. These results suggest that anti-RBD may serve as a harbinger for vaccine effectiveness (VE), and it should be explored as a predictor of breakthrough infections and VE.</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/35214743?dopt=Abstract</style></custom1></record></records></xml>